Last reviewed · How we verify
Endocrine Therapy 1 (endocrine-therapy-1)
Endocrine Therapy 1 (generic name: endocrine-therapy-1) is a Endocrine Therapy 1 drug developed by Pfizer Inc.. It is currently in discontinued development.
Endocrine Therapy 1
Endocrine therapy is a treatment approach used to study conditions such as breast cancer, pancreatic neuroendocrine tumors in MEN1, and high-risk localized prostate carcinoma, among others. It involves the use of medications like letrozole, anastrozole, exemestane, or tamoxifen, which target the endocrine system to treat these conditions.
At a glance
| Generic name | endocrine-therapy-1 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Endocrine Therapy 1 |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Endocrine Therapy 1 works by interfering with the body's hormone system to fight cancer. Certain cancers depend on hormones like estrogen or testosterone to survive and grow. By reducing these hormones or blocking their ability to attach to cancer cells, this medication starves tumors of the signals they need to proliferate. The drug essentially works as a brake on hormone-driven cancer growth. When cancer cells lose access to the hormones they rely on, they either stop dividing or die off entirely. This approach has proven effective because it targets the specific weakness of these hormone-dependent tumors without affecting all cells in the body equally. Patients taking this therapy typically have cancers that have been identified as hormone-responsive, meaning doctors confirmed the tumors grow in response to specific hormones. By controlling hormone levels or their activity, this medication can slow disease progression and improve survival for affected patients.
Approved indications
Pipeline indications
- HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer — discontinued
Common side effects
Key clinical trials
- Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurre (discontinued)
- To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutane (discontinued)
- Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Ede (discontinued)
- Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) (discontinued)
- A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction (discontinued)
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have (discontinued)
- Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiolo (discontinued)
- A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 (discontinued)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endocrine Therapy 1 CI brief — competitive landscape report
- Endocrine Therapy 1 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Endocrine Therapy 1
What is Endocrine Therapy 1?
How does Endocrine Therapy 1 work?
Who makes Endocrine Therapy 1?
What is the generic name of Endocrine Therapy 1?
What drug class is Endocrine Therapy 1 in?
What development phase is Endocrine Therapy 1 in?
Related
- Drug class: All Endocrine Therapy 1 drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing